Flecainide

Flecainide 구조식 이미지
카스 번호:
54143-55-4
상품명:
Flecainide
동의어(영문):
Flecaine;Flecanide;FLECAINIDE;Flecainide-d4;rac Flecainide;FLECAINTDE BASE;Flecainide USP/EP/BP;(±)-Flecainide solution;N-(Piperidin-2-ylmethyl);-2,5-bis(2,2,2-trifluoroethoxy)
CBNumber:
CB0663265
분자식:
C17H20F6N2O3
포뮬러 무게:
414.34
MOL 파일:
54143-55-4.mol

Flecainide 속성

녹는점
105-1070C
끓는 점
434.9±45.0 °C(Predicted)
밀도
1.286±0.06 g/cm3(Predicted)
인화점
9℃
저장 조건
Keep in dark place,Inert atmosphere,Room temperature
용해도
클로로포름(약간 용해됨), 메탄올(약간 용해됨)
물리적 상태
고체
물리적 상태
단단한 모양
산도 계수 (pKa)
pKa 9.3 (Uncertain)
색상
흰색에서 황백색까지
BCS Class
1 or 2?
CAS 데이터베이스
54143-55-4(CAS DataBase Reference)
NIST
Benzamide, n-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-(54143-55-4)
안전
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
위험품 표기 F,T
위험 카페고리 넘버 11-23/24/25-39/23/24/25
안전지침서 7-16-36/37-45
유엔번호(UN No.) 3249
WGK 독일 1
위험 등급 6.1(b)
포장분류 III
그림문자(GHS): GHS hazard pictogramsGHS hazard pictogramsGHS hazard pictograms
신호 어: Danger
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H225 고인화성 액체 및 증기 인화성 액체 구분 2 위험 GHS hazard pictograms P210,P233, P240, P241, P242, P243,P280, P303+ P361+P353, P370+P378,P403+P235, P501
H370 장기(또는, 영향을 받은 알려진 모든 장기를 명시)에 손상을 일으킴(노출되어도 특정 표적장기 독성을 일으키지 않는다는 결정적인 노출경로가 있다면 노출경로를 기재) 특정 표적장기 독성 - 1회 노출 구분 1 위험 GHS hazard pictograms P260, P264, P270, P307+P311, P321,P405, P501
예방조치문구:
P210 열·스파크·화염·고열로부터 멀리하시오 - 금연 하시오.
P260 분진·흄·가스·미스트·증기·...·스프레이를 흡입하지 마시오.
P280 보호장갑/보호의/보안경/안면보호구를 착용하시오.
P301+P310 삼켰다면 즉시 의료기관(의사)의 진찰을 받으시오.
P311 의료기관(의사)의 진찰을 받으시오.

Flecainide C화학적 특성, 용도, 생산

개요

From the chemical point, flecainide is an analog of procainamide, to which a 2.2.2-trifluoroethoxyl group was added at C2 and C3 of the benzene ring, and a diaminoethyl side chain is ended in the piperidine ring.

화학적 성질

White Crystalline Powder

용도

Flecainide, as with other local anesthetics, is used for naturally occurring ventricular arrhythmia.

정의

ChEBI: A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prev nt and treat tachyarrhythmia (abnormal fast rhythm of the heart).

World Health Organization (WHO)

The membrane-stabilizing antiarrhythmic agent flecainide was introduced into medicine in 1982. The decision to delete the indications for patients with asymptomatic and less severe symptomatic ventricular arrhythmias was taken on the basis of the results of a trial (CAST study) that showed a two-fold increase in deaths in post-myocardiac patients taking flecainide compared with the placebo group.

위험도

Human systemic effects.

Clinical Use

Flecainide (Tambocor) is a fluorinated aromatic hydrocarbon examined initially for its local anesthetic action and subsequently found to have antiarrhythmic effects. Flecainide inhibits the sodium channel, leading to conduction slowing in all parts of the heart, but most notably in the His-Purkinje system and ventricular myocardium. It has relatively minor effects on repolarization. Flecainide also inhibits abnormal automaticity.
Flecainide is effective in treating most types of atrial arrhythmias. It is also used for life-threatening ventricular arrhythmias. However, flecainide should be used with extreme caution in any patient with structural heart disease. Flecainide crosses the placenta, with fetal levels reaching approximately 70% of maternal levels. In many centers, it is the second-line drug after digoxin for therapy of fetal arrhythmias. Because of the high incidence of proarrhythmia, initiation of therapy or significant increases in dosing should be performed only on inpatients.

부작용

Most adverse effects occur within a few days of initial drug administration. The most frequently reported effects are dizziness, light-headedness, faintness, unsteadiness, visual disturbances, blurred vision (e.g., spots before the eyes, difficulty in focusing), nausea, headache, and dyspnea.
Worsening of heart failure and prolongation of the PR and QRS intervals are likely to occur with flecainide, and an increased risk of proarrhythmia has been reported.

Drug interactions

In patients whose condition has been stabilized by flecainide, the addition of cimetidine may reduce the rate of flecainide’s hepatic metabolism, increasing the potential for toxicity. Flecainide may increase digoxin concentrations on concurrent administration.

주의 사항

Flecainide is contraindicated in patients with preexisting second- or third-degree heart block or with bundle branch block unless a pacemaker is present to maintain ventricular rhythm. It should not be used in patients with cardiogenic shock.

Flecainide 준비 용품 및 원자재

원자재

준비 용품


Flecainide 공급 업체

글로벌( 116)공급 업체
공급자 전화 이메일 국가 제품 수 이점
Hangzhou FandaChem Co.,Ltd.
008657128800458; +8615858145714
fandachem@gmail.com China 9341 55
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795
ivan@atkchemical.com China 32686 60
CONIER CHEM AND PHARMA LIMITED
+8618523575427
sales@conier.com China 49391 58
career henan chemical co
+86-0371-86658258 15093356674;
factory@coreychem.com China 29826 58
Shaanxi Dideu Medichem Co. Ltd
+86-29-87569265 +86-18612256290
1056@dideu.com China 3082 58
TargetMol Chemicals Inc.
+1-781-999-5354 +1-00000000000
marketing@targetmol.com United States 19892 58
Hefei TNJ Chemical Industry Co.,Ltd.
0551-65418671
sales@tnjchem.com China 34572 58
Shaanxi Dideu Medichem Co. Ltd
+86-029-89586680 +86-18192503167
1026@dideu.com China 9126 58
AFINE CHEMICALS LIMITED
0571-85134551 18958018566;
info@afinechem.com China 15377 58
Finetech Industry Limited
+86-27-87465837 +8618971612321
info@finetechnology-ind.com China 9634 58

Flecainide 관련 검색:

Copyright 2019 © ChemicalBook. All rights reserved